Clinical and Prognostic Significance of Detecting , , , and MRNA-positive Cells in the Peripheral Blood, Tumor-draining Blood and Bone Marrow of Non-small Cell Lung Cancer Patients

Overview

Journal Transl Lung Cancer Res

Date 2023 Jun 16

PMID 37323172

Authors

Alona Rehulkova

Josef Chudacek

Andrea Prokopova

Monika Vidlarova

Jana Stranska

Jiri Drabek

Jana Potockova

Radek Trojanec

Jana Vrbkova

Josef Skarda

Tomas Bohanes

Marek Szkorupa

Benjamin Tolmaci

JIri Klein

Josef Srovnal

Marian Hajduch

Affiliations

Soon will be listed here.

Abstract

Background: Surgical treatment of early-stage non-small cell lung cancer (NSCLC) yields highest expectations for recovery. However, the frequency of further disease progression remains high since micro-metastatic disease may be undetected by conventional diagnostic methods. We test the presence and prognostic impact of circulating tumor cells (CTCs) in peripheral blood (PB), tumor-draining pulmonary blood (TDB) and bone marrow (BM) samples from NSCLC patients.

Methods: The presence of circulating/disseminated tumor cells (CTCs/DTCs) was detected by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) analysis in PB, TDB and BM samples before surgery in 119 stage IA-IIIA NSCLC patients (Clinical Trial NS10285).

Results: NSCLC patients with the presence of carcinoembryonic antigen () mRNA-positive CTCs/DTCs in TDB and BM had significantly shorter cancer-specific survival (CSS) (P<0.013, resp. P<0.038). Patients with the presence of epithelial cellular adhesion molecule () mRNA-positive CTCs in TDB samples had significantly shorter CSS and disease-free survival (DFS) (P<0.031, resp. P<0.045). A multivariate analysis identified the presence of mRNA-positive CTCs in the PB as an independent negative prognostic factor for DFS (P<0.005). No significant correlation of CTCs/DTCs presence and other prognostic factors was found.

Conclusions: In NSCLC patients undergoing radical surgery, the presence of and mRNA-positive CTCs/DTCs is associated with poorer survival.

References

Ligthart S, Coumans F, Attard G, Mulick Cassidy A, de Bono J, Terstappen L . Unbiased and automated identification of a circulating tumour cell definition that associates with overall survival. PLoS One. 2011; 6(11):e27419. PMC: 3210171. DOI: 10.1371/journal.pone.0027419. View

Cote R, BEATTIE E, Chaiwun B, Shi S, Harvey J, Chen S . Detection of occult bone marrow micrometastases in patients with operable lung carcinoma. Ann Surg. 1995; 222(4):415-23; discussion 423-5. PMC: 1234868. DOI: 10.1097/00000658-199522240-00001. View

Sienel W, Seen-Hibler R, Mutschler W, Pantel K, Passlick B . Tumour cells in the tumour draining vein of patients with non-small cell lung cancer: detection rate and clinical significance. Eur J Cardiothorac Surg. 2003; 23(4):451-6. DOI: 10.1016/s1010-7940(02)00865-5. View

Franken B, de Groot M, Mastboom W, Vermes I, van der Palen J, Tibbe A . Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer. Breast Cancer Res. 2012; 14(5):R133. PMC: 4053111. DOI: 10.1186/bcr3333. View

Cohen E, Jayachandran G, Moore R, Cristofanilli M, Lang J, Khoury J . A Multi-Center Clinical Study to Harvest and Characterize Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the Parsortix PC1 System. Cancers (Basel). 2022; 14(21). PMC: 9656921. DOI: 10.3390/cancers14215238. View

Sawabata N, Funaki S, Hyakutake T, Shintani Y, Fujiwara A, Okumura M . Perioperative circulating tumor cells in surgical patients with non-small cell lung cancer: does surgical manipulation dislodge cancer cells thus allowing them to pass into the peripheral blood?. Surg Today. 2016; 46(12):1402-1409. DOI: 10.1007/s00595-016-1318-4. View

Poncelet A, Weynand B, Ferdin F, Robert A, Noirhomme P . Bone marrow micrometastasis might not be a short-term predictor of survival in early stages non-small cell lung carcinoma. Eur J Cardiothorac Surg. 2001; 20(3):481-8. DOI: 10.1016/s1010-7940(01)00830-2. View

Banys-Paluchowski M, Krawczyk N, Meier-Stiegen F, Fehm T . Circulating tumor cells in breast cancer--current status and perspectives. Crit Rev Oncol Hematol. 2015; 97:22-9. DOI: 10.1016/j.critrevonc.2015.10.010. View

Hashimoto M, Tanaka F, Yoneda K, Takuwa T, Matsumoto S, Okumura Y . Significant increase in circulating tumour cells in pulmonary venous blood during surgical manipulation in patients with primary lung cancer. Interact Cardiovasc Thorac Surg. 2014; 18(6):775-83. DOI: 10.1093/icvts/ivu048. View

10.

Sawabata N, Nakamura T, Kawaguchi T, Watanabe T, Ouji N, Ito T . Circulating tumor cells detected only after surgery for non-small cell lung cancer: is it a predictor of recurrence?. J Thorac Dis. 2020; 12(9):4623-4632. PMC: 7578482. DOI: 10.21037/jtd-20-1636. View

11.

Kongsgaard A, Borgen E, Maelandsmo G, Flatmark K, Le H, Josefsen D . Clinical significance of disseminated tumour cells in non-small cell lung cancer. Br J Cancer. 2013; 109(5):1264-70. PMC: 3778301. DOI: 10.1038/bjc.2013.450. View

12.

Lv C, Zhao B, Wang L, Zhang P, Ma Y, Wang Y . Detection of circulating tumor cells in pulmonary venous blood for resectable non-small cell lung cancer. Oncol Lett. 2018; 15(1):1103-1112. PMC: 5772954. DOI: 10.3892/ol.2017.7405. View

13.

Iwao K, Watanabe T, Fujiwara Y, Takami K, Kodama K, Higashiyama M . Isolation of a novel human lung-specific gene, LUNX, a potential molecular marker for detection of micrometastasis in non-small-cell lung cancer. Int J Cancer. 2001; 91(4):433-7. DOI: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1059>3.0.co;2-b. View

14.

Breitenbuecher F, Hoffarth S, Worm K, Cortes-Incio D, Gauler T, Kohler J . Development of a highly sensitive and specific method for detection of circulating tumor cells harboring somatic mutations in non-small-cell lung cancer patients. PLoS One. 2014; 9(1):e85350. PMC: 3897440. DOI: 10.1371/journal.pone.0085350. View

15.

Goldstraw P, Crowley J, Chansky K, Giroux D, Groome P, Rami-Porta R . The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007; 2(8):706-14. DOI: 10.1097/JTO.0b013e31812f3c1a. View

16.

Bustin S, Benes V, Garson J, Hellemans J, Huggett J, Kubista M . The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009; 55(4):611-22. DOI: 10.1373/clinchem.2008.112797. View

17.

Hsu C, Shai S, Hsia J, Chen C . Clinical significance of bone marrow microinvolvement in nonsmall cell lung carcinoma. Cancer. 2004; 100(4):794-800. DOI: 10.1002/cncr.20027. View

18.

Li J . Significance of Circulating Tumor Cells in Nonsmall-Cell Lung Cancer Patients: Prognosis, Chemotherapy Efficacy, and Survival. J Healthc Eng. 2021; 2021:2680526. PMC: 8594996. DOI: 10.1155/2021/2680526. View

19.

Almufti R, Wilbaux M, Oza A, Henin E, Freyer G, Tod M . A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment. Ann Oncol. 2013; 25(1):41-56. DOI: 10.1093/annonc/mdt382. View

20.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View